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E-mail address: mlbastos@ff.up.pt (Maria de LourdSuccessful application of gold nanoparticles (AuNPs) in biomedicine requires extensive safety assessment
for which biokinetic studies are crucial.
We evaluated the biodistribution of AuNPs (20 nm) with different surface coatings: citrate, 11-MUA
and 3 pentapeptides, CALNN, CALND and CALNS, after i.v. administration to rats (0.6–1 mg Au/kg). Bio-
distribution was evaluated based on Au tissue content measured by GFAAS.
Citrate-AuNPs were rapidly removed from circulation with 60% of the injected dose depositing in the
liver. Thirty minutes post-injection, the lungs presented about 6% of the injected dose with levels
decreasing to 0.7% at 24 h. Gold levels in the spleen were of 2.6%. After 24 h, liver presented the highest
Au level, followed by spleen and blood.
A similar biodistribution proﬁle was observed for MUA-coated AuNPs compared to Cit-AuNPs at 24 h
post-injection, while signiﬁcantly higher levels of peptide-capped AuNPs were found in the liver (74–
86%) accompanied by a corresponding decrease in blood levels.
TEM analysis of liver slices showed AuNPs in Kupffer cells and hepatocytes, trapped inside endosomes.
Our data demonstrate that AuNPs are rapidly distributed and that the liver is the preferential accumu-
lation organ. Peptide capping signiﬁcantly increased hepatic uptake, showing the inﬂuence of AuNPs
functionalization in biodistribution.
 2011 Elsevier B.V. All rights reserved.1. Introduction
Nanotechnology has quickly developed in the last few years,
giving birth to nanomaterials, with application in areas including,
textile, electronics, cosmetics and medicine. Due to unique optical
and thermal properties, gold nanoparticles (AuNPs) constitute
promising candidates in biomedicine to be applied in diagnostic
aid [1], drug and gene delivery [2] and photothermal cancer ther-
apy [3,4]. However, despite great potential, concerns regarding
their safety have been raised and need to be properly addressed.ll rights reserved.
acid; Au, gold; AuNPs, gold
Cys-Ala-Leu-Asn-Asn; CALNS,
g; i.p., intraperitoneal; i.v.,
orption Spectrometry; NPs,
loendothelial system; SEM,
ron microscopy; XPS, photo-
f Toxicology, Department of
Porto, Rua Aníbal Cunha 164,
+351 222003977.
es Bastos).In safety assessment, biokinetic studies are crucial to under-
stand how the different properties of the AuNPs affect their biodis-
tribution proﬁle, residence time, metabolism and elimination from
the organism. Factors such as shape, size, surface coating and
charge affect their physicochemical properties and are therefore
expected to inﬂuence interactions with biological systems [5]. Re-
ports on in vivo biodistribution of AuNPs are so far scarce and
mainly focused on the kinetics of citrate-coated AuNPs after intra-
venous (i.v.) injection in rat [6,7] and mouse [8–10]. The bioavail-
ability of orally administered AuNPs has also been studied in these
animal models [10–12]. These studies have shown that size is one
of the major determinants of biodistribution [7,9,13]. Also, the liver
and spleen have been consistently found to be the main reservoir
organs for these metallic NPs [6,7,9,14,15] that are rapidly re-
moved from the systemic circulation by the reticuloendothelial
system (RES).
Functionalization through the addition of ligands on the surface
of the AuNPs is of great interest as capping can confer some stealth
capacity to remain undetected by the RES, thus prolonging their
half-life in the bloodstream [16]. In addition, coating can also be
employed as a targeting strategy to guide the NPs to a desired
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ure including polymers like polyethylene glycol (PEG) [16] and
peptides [18]. Peptides as surface capping agents of AuNPs are
advantageous as they can increase stability, biocompatibility and
solubility in water [18]. However, knowledge on how these pep-
tides interact and pack on a NP surface and how their anchorage
affects molecular recognition of the biological target and the stabil-
ity of the NPs is still scarce [19]. Studies on PEG-coated AuNPs bio-
distribution have shown that these NPs exhibit longer blood
circulation times both in mice [13,14,20,21] and in rats [22] com-
pared to their uncoated counterparts. Nevertheless, liver and
spleen remained the preferential sites of the accumulation of the
PEG-AuNPs. Recently, a study by Guerrero et al. [23] demonstrated
that conjugation of the amphipathic peptide CLPFFD to the AuNP
surface increased in vivo brain delivery, while simultaneously
reducing its retention in the spleen 1 and 2 h after intraperitoneal
(i.p.) injection in the rat, as compared with citrate-coated AuNPs of
the same size. These studies demonstrate that functionalization af-
fects NPs in vivo kinetics and biodistribution. Hence, the present
study aimed to evaluate the effect of surface coating on the biodis-
tribution of AuNPs in the rat after a single i.v. administration. Five
different coatings were investigated including (i) citrate, (ii) 11-
mercaptoundecanoic acid (11-MUA) and the pentapeptides, (iii)
Cys-Ala-Leu-Asn-Asn (CALNN), (iv) Cys-Ala-Leu-Asn-Ser (CALNS)
and (v) Cys-Ala-Leu-Asn-Asp (CALND). Citrate and 11-MUA were
selected since these are the most common capping agents for AuN-
Ps, whereas the pentapeptides have been considered particularly
resistant to aggregation and precipitation in complex media [24].
The gold (Au) content in all the collected tissues was quantiﬁed
by Graphite Furnace Atomic Absorption Spectrometry (GFAAS).
The AuNPs translocation from the systemic circulation into the li-
ver and their hepatic subcellular localization was further evaluated
by transmission electron microscopy (TEM).2. Materials and methods
2.1. Reagents and standards
All chemicals used were of high purity or analytical grade. Nitric
acid (HNO3), hydrogen peroxide (H2O2), palladium (II) nitrate
[Pd(NO3)2], magnesium nitrate [Mg(NO3)2] and hydrochloric acid
(HCl) were purchased from Merck (Germany). Gold pure calibra-
tion standard was obtained from Perkin–Elmer (USA). Tetrachloro-
auric acid (HAuCl4; 30 wt%), sodium citrate (Na3Cit) and 11-MUA
were purchased from Sigma–Aldrich (Spain). The pentapeptides
CALNN, CALND and CALNS were synthesized with a cysteine amino
acid at the N-terminus for binding onto the AuNPs. Na-Fmoc-pro-
tected amino acids and Fmoc-Asn(Trt)-Wang resin used for peptide
synthesis were from Novabiochem (VWR International), whereas
solvents [N,N-dimethylformamide (DMF) and dichloromethane
(DCM)] as well as reagents for amino acid coupling [N,N-diisopro-
pylcarbodiimide, (DIC)] and deprotection (piperidine) were all
from Sigma–Aldrich (Spain).2.2. Synthesis and characterization of AuNPs
Gold nanoparticles (AuNPs) were synthesized under sterile con-
ditions according to the Turkevich method [25,26] with slight
modiﬁcations. Brieﬂy, 62.5 mL of 1.4 mM HAuCl4 was brought to
the boil while stirring in a round-bottom ﬂask, and 6.25 mL of a
solution of 36.8 mM Na3Cit was quickly added and heated for an-
other 15 min. The solution was then allowed to cool at room tem-
perature. Exchange of the capping agent was performed as
previously described [24], using a molar ratio capping agent/
[AuNP] of 120. Four capping agents were employed: 11-MUA and3 pentapeptides, CALNN, CALNS and CALND. CALNN sequence is
constituted by an N-terminal cysteine (C) residue followed by an
alanine (A), leucine (L) and two asparagine (N) residues. CALNS
and CALND share the initial sequence of CALNN, only differing in
its C-terminal residues, serine (S) and aspartic acid (D),
respectively.
The peptides (C-terminal carboxyl) were assembled by classical
Fmoc/tBu solid-phase peptide synthesis methodologies [27], on a
pre-loaded Fmoc-Asn(Trt)-Wang resin [28]. In brief, after the re-
moval of the Fmoc-protecting group from the pre-loaded resin
with 20% piperidine in DMF, the remaining four amino acids were
sequentially coupled in the C? N direction by means of standard
coupling + deprotection cycles. All the coupling reactions were car-
ried out during ca. 60 min, using 5-M excesses of both the relevant
Fmoc-protected amino acid and the coupling reagent (DIC) and
using DCM or DCM/DMF mixtures as solvents. Deprotection reac-
tions were done by treatment of the resin with 20% piperidine in
DMF (1 min + 20 min). Both coupling and deprotection were re-
peated until completion, which was veriﬁed by the ninhydrin or
Kaiser assay [29]. After being assembled, the peptides were fully
deprotected and cleaved from the resin by acidolysis (3 h) of the
peptidyl-resin using a triﬂuoroacetic acid (TFA)-based cocktail
[27] containing water and triisopropylsilane (TIS) as scavengers
(TFA/H2O/TIS 95:2.5:2.5 v/v/v). The crude product was puriﬁed
by reverse-phase liquid chromatography, and the ﬁnal product
was analyzed by HPLC, ESI-IT MS and amino acid analysis.
Before utilization, NPs were washed (3) by centrifugation in
centricon ﬁlter units (cut-off 30 kDa) followed by dispersion in
water. Gold nanoparticle concentration was determined by UV/
Vis spectroscopy by the method of Haiss et al. [30]. Concentration
of Au in the suspensions to be injected in the rats was determined
by GFAAS. The average particle size of the initial batch (citrate) was
determined by TEM using a HITACHI H-8100 microscope operated
at 200 kV. The hydrodynamic diameter and zeta potential were
measured by Dynamic Light Scattering (DLS) using a Zeta Sizer
Nano ZS (Malvern Instruments, Ltd.), with a laser 4 mWHe-Ne
(633 nm), at 25 C. Photoelectron spectroscopy (XPS) experiments
were performed in a VG Scientiﬁc ESCALAB 200A spectrometer
using non-monochromatic Al Ka radiation (1486.6 eV, Materials
Centre of the University of Porto, CEMUP). Corrections for sample
charge were made by taking the C 1s band at 285.0 V as internal
standard. The colloidal solutions for XPS measurements were cen-
trifuged at 60,000 rpm for 10 min at room temperature, and the
pellet was deposited on a graphite support.
2.3. Animals and experimental design
Male Wistar rats (Charles River Laboratories, Barcelona, Spain)
with a body weight ranging from 200 to 300 g were used in this
study. All the procedures were carried out in accordance with
the Guide for the Care and Use of Laboratory Animals from the
Institute for Laboratory Animal Research [31]. The animals were
housed in metabolic cages, with a temperature and humidity con-
trolled environment. Food and water were provided ad libitum and
animals were subjected to a 12 h light/dark cycle. Rats were di-
vided into ﬁve experimental groups (n = 4 per group) and a control
group (n = 2). The animals were lightly anaesthetized with sodium
thiopental (i.p., 30 mg/kg), prior to the injection of AuNPs. The
AuNPs suspensions were sonicated in an ultrasound bath (Bandelin
Sonorex RK 100H) for 5 min to ensure complete dispersion of the
AuNPs. In order to accurately determine the injected dose and ac-
count for the volume of suspension left in the syringe, two aliquots
of the AuNPs suspensions were taken. One of the aliquots was in-
jected into the animal and the other was discarded to a vial for
determination of the Au content by GFAAS. The amount of solution
remaining in the syringe dead space did not change signiﬁcantly
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injected dose. The tested dose for each different type of functional-
ized AuNPs differed slightly due to variations in the Au concentra-
tion between batches (Table 1). Pilot experiments showed that the
injection procedure is crucial for the rigorous administration of
AuNPs solutions, being the volume injected determinant to the
amount retained in the injection point. We veriﬁed that in order
to obtain consistent results the volume of the AuNPs suspensions
and the velocity of injection required standardization. Thus, we
chose to inject the same volume of the suspension instead of
adjusting the volume to obtain the same dose. Therefore, a single
injection of 1 mL of each suspension of AuNPs (citrate-, MUA-, CAL-
NN-, CALNS- or CALND-coated) was slowly administered in the tail
vein at an accurate dose of Au in the range of 0.6–1 mg/kg body
weight. In consequence, for comparisons, all data calculations were
made in terms of% of the injected dose. The control group (n = 2)
received 1 mL of a saline solution (0.9% NaCl).
At the selected time points (30 min, 2 h, 6 h and 24 h for Cit-
AuNPs and 24 h for the functionalized AuNPs), rats were anaesthe-
tized with sodium thiopental (i.p., 60 mg/kg) and sacriﬁced. Blood
was withdrawn into heparinized tubes, and organs/tissues includ-
ing heart, liver, lung, spleen, kidney, testis, small intestine (duode-
num), bone (shaft of femur), skeletal muscle (quadricepts femoris),
brain and tail were collected. Urine and feces were separately col-
lected in the metabolic cages. All surgical instruments were exten-
sively washed throughout the procedure to avoid cross-
contamination. The organs were washed in saline solution (NaCl
0.9%), dried in blotting paper and stored at 80 C until analysis.
Whole blood was stored at 4–6 C.2.4. Analytical procedure for determination of gold in biological
samples
2.4.1. Digestion of biological samples
Samples were weighed on a precision balance (Mettler Toledo
PB302, Germany), followed by acid digestion in Teﬂon containers
with a mixture of 65% HNO3 and 30% H2O2 (4:1). Five milliliters
of blood, 1 g of homogenized liver and the whole tissue of heart,
lung, spleen, kidney, testis, duodenum, shaft of femur, skeletal
muscle (quadricepts femoris), brain and tail tissues were taken for
digestion. After digestion at 105 C for 24 h, the samples were al-
lowed to cool at room temperature and 37% HCl was added. Then,
the samples were placed again in the oven at 105 C for 24 h. At the
end of the incubation time, samples were transferred into a tube
and stored in the dark at room temperature, prior to the Au
quantiﬁcation.2.4.2. Validation of the method
For calibration purposes, a stock solution of Au (1000 lg/mL)
and its corresponding dilutions were used to determine the linear-Table 1
Main characteristics of the AuNPs used in this study. The average size and
of the suspensions was determined by GFAAS.
NP coating Hydrodynamic radiusa (nm) Zeta p
Citrate 22.4 (5.7) 44.7
MUA 33.2 (9.8) 37.3
CALNN 33.7 (9.6) 47.1
CALND 35.1 (9.9) 43.6
CALNS 34.9 (9.6) 40.5
a The values in parenthesis are polydispersion indexes.
b Results are expressed as means ± standard deviation.
c The concentration of NPs was determined by UV/Vis for the citrate
d The concentration of Au of the injected colloidal suspensions were
error of the mean.ity range (0.65–50 ng/mL) and to evaluate the limits of detection
and quantiﬁcation, which were 0.65 and 2.15 ng/mL, respectively.
The accuracy of the method was evaluated by the standard addi-
tions method in liver, lung, spleen, kidney and blood of untreated
rats. The values expressed as% of recovery ranged from 85.8 to
109. The precision expressed as% cv ranged from 1.4 to 6.4.2.4.3. Graphite Furnace Atomic Absorption Spectrometry (GFAAS)
Elemental gold content of the acid-digested samples was deter-
mined by GFAAS using a Perkin–Elmer AAnalyst 600 Atomic
Absorption Spectrophotometer (USA) equipped with an autosam-
pler. Analyses were carried out at 242.8 nm, and the readings were
taken by using the peak area. The autosampler was programmed to
pipette sequentially 10 lL of the modiﬁer [3 g/L Pd(NO3)2 + 2 g/L
Mg(NO3)2] followed by 20 lL of the standard solution/sample solu-
tion and to dispense them together onto the platform. Each di-
gested sample was further diluted suitably, depending on the
tissue type and amount using 0.2% HCl prior to analysis and thor-
oughly vortexed before autosampler was withdrawn. All GFAAS
analyses were conducted at an ashing temperature of 800 C, at
an atomization temperature of 1800 C and with Zeeman back-
ground correction.2.5. Transmission electron microscopy (TEM) of biological samples
Transmission electron microscopy was performed to assess the
uptake and subcellular localization of AuNPs in the liver tissue.
Slices of liver from the animals sacriﬁced 24 h post-injection (one
animal per group) were randomly removed and ﬁxed with 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer for 4 h. The spec-
imens were postﬁxed with 2% osmium tetroxide, dehydrated
through graded alcohol solutions and embedded in Epon. Ultrathin
sections (100 nm) mounted on copper grids (300 mesh) were con-
trasted with uranyl acetate and lead citrate for TEM analysis (Zeiss
EM 10A; Carl Zeiss, Oberkochen, Germany) at an accelerating volt-
age of 60 kV. To obtain a global characterization of the liver, several
grids were prepared (5–8 grids per animal, each one having 3–4
sectioning cuts) from the different hepatic lobes.2.6. Statistical analysis
Results are expressed as mean ± the standard error of the mean
(SEM) from four independent experiments. Statistical analysis was
performed using the SigmaPlot 11 software. Non-parametric tests
and comparisons between groups were performed with the Krus-
kal–Wallis test (one-way ANOVA on ranks) followed by the Stu-
dent–Newman–Keuls post hoc test. Signiﬁcance was accepted at a
p value 60.05.zeta potential of the AuNPs were determined by DLS. The Au content
otentialb (mV) [NP]c (nM) [Au]d (lg/mL)
± 7.5 4.67 249.0 ± 35.3
± 8.4 4.44 236.5 ± 15.4
± 6.0 3.45 152.2 ± 14.5
± 9.2 2.85 184.0 ± 25.5
± 7.0 2.96 158.1 ± 6.9
-AuNPs and estimated for the other NPs.
determined by GFAAS. Results are expressed as means ± standard
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3.1. Synthesis and characterization of AuNPs
The main characteristics of the different negatively charged
AuNPs used in our study are summarized in Table 1 and Fig. 1.
Spherical citrate-stabilized AuNPs (Cit-AuNPs) were prepared as
previously described [26] in strictly aseptic conditions. The average
NP diameter measured by TEM was 18.4 ± 4.9 nm (n = 134 NPs).
This agrees well with the hydrodynamic diameter determined by
DLS, shown in Table 1. The difference in the average diameters
determined by the two techniques is expected considering that
TEM measures the size of the electron-dense Au core, whereas
DLS also measures the capping agent shell and the hydration
sphere of the NPs. After exchange of the capping agent, there is a
small increase in the hydrodynamic diameter and polydispersion
index, probably due to the different surface properties imparted
by the capping agents. Zeta potential of the colloidal dispersions
of NPs was also determined, and the results are shown in Table 1.
All the NPs show a high negative surface charge due to the nega-
tively charged carboxylate moiety of MUA and the peptides. It is
to be noted that the three peptides used are expected to adsorb
at the surface of the NPs through the cysteine residue at the N-ter-
minal, with the anionic C-terminal oriented towards the solution.
To conﬁrm the exchange of the capping agent for the three pep-
tides, XPS analysis of the NPs was performed, showing the pres-
ence of Au and S. The binding energies measured (84.0 and
87.7 eV for Au 4f7/2 and 4f5/2, respectively, and 162 eV for S2p)
are typical of AuNPs with thiolate capping agents [32]. RelativeFig. 1. (A) Representative TEM image of citrate-AuNPs. The bar represents 200 nm; (B) hi
(N = 143 particles); (C) UV/Vis spectra of colloidal solutions of AuNPs capped with citra
diameters measured by DLS for AuNPs with the different capping agents. (For interpreta
version of this article.)atomic amounts of sulfur (CALNN: 3.93%; CALND: 6.69%; CALNS
3.08%) and Au (CALNN: 89.3%; CALND: 89.2%; CALNS 89.1%) are
within the range usually observed for AuNPs with thiolate capping
agents.
The concentration of Cit-AuNPs was evaluated by UV/Vis spec-
troscopy using the method of Haiss et al. [30] and estimated for the
other NPs (Table 1). Before injection, the Au contents of the AuNPs
suspensions ([Au] in lg/mL) were determined by the validated
GFAAS (Table 1).
3.2. Biodistribution of AuNPs in the rat
3.2.1. Biodistribution proﬁle of the citrate-coated AuNPs
The biodistribution proﬁle of the AuNPs in the rat organism was
evaluated based on the Au content present in the biological sam-
ples collected from AuNPs-administered rats. The elemental gold
was determined by GFAAS, a technique considered to be suitable
to monitor the biodistribution of AuNPs [33]. The kinetics of distri-
bution of citrate-coated AuNPs (Cit-AuNPs) at the selected time
points (0.5, 2, 6 and 24 h) in ng/g organ is shown in Table 2. Ana-
lyzing the amount of Au found, the highest concentrations were
found in the liver (14,801 ± 839 ng/g) followed by the spleen
(5480 ± 1116 ng/g). The lung showed a high Au content 30 min
after injection (9228 ± 3316 ng/g), but levels decreased very rap-
idly with time down to 1886 ± 1169 ng/g at 24 h. The liver was
the preferential site for accumulation of the citrate-coated AuNPs,
with values as high as 60% of the injected dose (Table 3). In the
spleen, Au was present at appreciable levels, similar to those found
in the tail, of about 3% of the injected dose. Traceable amounts ofstogram of size distribution of citrate-AuNPs with an average diameter of 18 ± 5 nm;
te, MUA and pentapeptides; (D) zeta potential distribution and (E) hydrodynamic
tion of the references to color in this ﬁgure legend, the reader is referred to the web
Table 2
Gold distribution in the analyzed rat organs 0.5–24 h after i.v. injection of Cit-AuNPs and 24 h after i.v. injection of the functionalized AuNPs (expressed as ng/g tissue).
Tissue Gold concentration (ng/g tissue)
Cit-AuNPs MUA-AuNPs CALNN-AuNPs CALND-AuNPs CALNS-AuNPs
0.5 h 2 h 6 h 24 h 24 h 24 h 24 h 24 h
Liver 15419 ± 1186 16810 ± 1202 16341 ± 2046 14801 ± 839 13884 ± 1269 9970 ± 3214 15436 ± 349 12153 ± 542
Spleen 10570 ± 1972 7352 ± 1796 7282 ± 1834 5480 ± 1116 8079 ± 1790 6059 ± 671 7572 ± 1797 4165 ± 412
Lungs 9228 ± 3316 1045 ± 102 1370 ± 296 1886 ± 1169 975 ± 368 739 ± 71 1838 ± 1112 814 ± 89
Blood 134 ± 42 392 ± 246 260 ± 92 189 ± 67 153 ± 91 25 ± 12 21 ± 9 38 ± 6
Heart 30 ± 15 114 ± 47 79 ± 42 151 ± 53 38 ± 24 20 ± 5 51 ± 28 25 ± 9
Kidney 41 ± 4 178 ± 134 101 ± 74 129 ± 37 41 ± 21 150 ± 50 60 ± 27 15 ± 9
Small intestine 12 ± 3 160 ± 57 82 ± 41 43 ± 17 19 ± 8 187 ± 72 9 ± 5 196 ± 73
Brain 8 ± 3 26 ± 10 59 ± 32 68 ± 53 36 ± 12 9 ± 5 38 ± 10 < LQ
Bone 1005 ± 937 935 ± 541 339 ± 103 575 ± 410 77 ± 51 94 ± 40 41 ± 17 42 ± 17
Muscle 26 ± 16 112 ± 50 74 ± 62 51 ± 51 37 ± 17 10 ± 8 37 ± 21 39 ± 16
Testis 15 ± 8 15 ± 16 53 ± 30 <LQ <LQ <LQ 16 ± 11 <LQ
Tail 941 ± 321 596 ± 164 419 ± 51 852 ± 236 1830 ± 779 870 ± 346 481 ± 144 484 ± 164
The results are presented as means ± SEM (n = 4); LQ (limit of quantiﬁcation).
Table 3
Kinetics of Au distribution in the analyzed rat organs after i.v. injection of Cit-AuNPs expressed as% of injected dose.
Tissue % of injected gold
0.5 h 2 h 6 h 24 h
Liver 57.75 ± 2.28 68.43 ± 7.01 74.53 ± 6.62 57.94 ± 2.57
Spleen 2.55 ± 0.38a 2.06 ± 0.50a 2.13 ± 0.31a 1.34 ± 0.23a
Lung 5.58 ± 2.40a 0.47 ± 0.04a,b,c,d 0.43 ± 0.11a 0.72 ± 0.44a
Blood 0.82 ± 0.24a 2.92 ± 1.86a 1.95 ± 0.80a 1.27 ± 0.43a
Heart 0.01 ± 0.00a 0.03 ± 0.01a,b,c,d,e 0.03 ± 0.01a 0.04 ± 0.01a,b,c,d,e
Kidney 0.03 ± 0.00a 0.13 ± 0.10a,b,c,d,e 0.08 ± 0.06a 0.08 ± 0.02a,b,c,d,e
Small intestine 0.01 ± 0.00a 0.07 ± 0.02a,b,c,d,e 0.03 ± 0.01a 0.02 ± 0.01a,b,c,d,e
Muscle 0.01 ± 0.00a 0.04 ± 0.02a,b,c,d,e 0.03 ± 0.03a 0.01 ± 0.01a,b,c,d,e
Brain 0.01 ± 0.00a 0.02 ± 0.01a,b,c,d,e 0.05 ± 0.03a 0.05 ± 0.04a,b,c,d,e
Bone 0.12 ± 0.10a 0.27 ± 0.15a,b,c,d,e 0.10 ± 0.05a 0.16 ± 0.10a,b,c,d,e
Testis 0.02 ± 0.01a 0.02 ± 0.02a,b,c,d,e 0.04 ± 0.04a 0.00 ± 0.01a,b,c,d,e
Tail 2.60 ± 0.89a 1.70 ± 0.51a 1.26 ± 0.13a 2.27 ± 0.67a
Total 67.81 ± 1.73 73.85 ± 5.45 73.71 ± 2.35 63.91 ± 2.89
Results are presented as means ± SEM (n = 4).
a 0.05 vs. Liver.
b 0.05 vs. Spleen.
c 0.05 vs. Tail.
d 0.05 vs. Blood.
e 0.05 vs. Lung.
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obtained in the other tissues were very close to the limit of quan-
tiﬁcation (2.15 ng/g). Although no statistically signiﬁcant differ-
ences were found in the amount of Au present in the organs
throughout the experiment, some trends could be observed (Ta-
ble 3). Thirty minutes after injection, the liver contained
57.75 ± 2.28% of the injected Au, peaked at 6 h (74.53 ± 6.62%)
but returned to the initial values (57.94 ± 2.57%) at 24 h. In the
spleen, Au levels decreased from 2.55 ± 0.38% at 30 min to
1.34 ± 0.23% at 24 h, showing a declining trend of Au concentration
in this organ. For the studied times, the highest blood Au concen-
tration was found at 2 h (2.36 ± 1.48%) followed by a steady de-
crease (1.14 ± 0.40% at 24 h). A small amount of the injected dose
was retained in the tail, but no differences were observed in those
values throughout the experiment. The total Au recovery in the
analyzed samples of the rat organism ranged from 64% to 74% of
the injected dose.
3.2.2. Biodistribution proﬁle of 11-MUA and pentapeptide-coated
AuNPs
The effect of 11-MUA and pentapeptide surface coating on the
biodistribution proﬁle of AuNPs was investigated 24 h after intra-
venous administration to rats. Regarding MUA-AuNPs, a similar
distribution pattern to the Cit-AuNPs has been observed (Table 4).High concentrations of Au were found in the liver, followed by tail,
spleen, blood and lungs. Corrected for the corresponding injected
dose, liver and spleen were the major accumulation sites for
MUA-AuNPs (Fig. 2).
Although pentapeptide-coated AuNPs shared the general pat-
tern of distribution with Cit-AuNPs, some signiﬁcant differences
in tissue Au contents were observed. Peptide-capped NPs were
widely distributed throughout the body, mainly present in liver,
spleen, and to a lesser extent in the lungs (Table 4). Twenty-four
hours after injection, 77.47 ± 2.52% of the total injected CALND-
AuNPs, 86.11 ± 7.13% of the CALNN-AuNPs and 73.66 ± 4.84% of
CALNS-AuNPs were retained in the liver (Fig. 2 and Table 4). These
values were signiﬁcantly higher than those found in the liver of the
citrate-coated AuNPs-treated rats. A signiﬁcantly lower% of the to-
tal injected Au was observed in blood from rats exposed to CALNN-
(0.32 ± 0.13%), CALNS- (0.38 ± 0.07%) and CALND-AuNPs
(0.19 ± 0.08%), in comparison with Cit-AuNPs-treated rats
(1.27 ± 0.43%). In addition to the liver, the spleen of the CALNN-
AuNPs-injected rats also acts as reservoir organ as evidenced by
the signiﬁcantly higher contents of Au comparing to the blood lev-
els. No differences in the Au levels retained in the tail were ob-
served for all the functionalized AuNPs-treated rats. Also, Au
levels found in urine and feces were always below the limit of
quantiﬁcation.
Table 4
Gold concentration in the analyzed rat organs 24 h after i.v. injection of the AuNPs (expressed as% of the injected dose).
Tissue % of injected gold
Citrate-AuNPs MUA-AuNPs CALNN-AuNPs CALND-AuNPs CALNS-AuNPs
Liver 57.94 ± 2.57 59.37 ± 4.08f,g 86.11 ± 7.13f,g 77.47 ± 2.52f,g 73.66 ± 4.84f,g
Spleen 1.34 ± 0.23a 2.26 ± 0.52a 2.79 ± 0.30a 2.51 ± 0.59a 1.88 ± 0.13a
Lung 0.72 ± 0.44a 0.44 ± 0.19a 0.53 ± 0.06a,b,c 0.88 ± 0.6a 0.52 ± 0.09a
Blood 1.27 ± 0.43a 1.13 ± 0.71a,f 0.32 ± 0.13a,b,c,f 0.19 ± 0.08a,f 0.38 ± 0.07a,f
Heart 0.04 ± 0.01a,b,c,d,e 0.01 ± 0.01a 0.01 ± 0.00a,b,c 0.02 ± 0.01a 0.01 ± 0.00a
Kidney 0.08 ± 0.02a,b,c,d,e 0.03 ± 0.01a 0.20 ± 0.07a,b,c 0.05 ± 0.02a 0.01 ± 0.00a
Small intestine 0.02 ± 0.01a,b,c,d,e 0.01 ± 0.00a 0.24 ± 0.09a,b,c 0.01 ± 0.01a 0.19 ± 0.06a
Muscle 0.01 ± 0.01a,b,c,d,e 0.01 ± 0.00a 0.00 ± 0.00a,b,c 0.01 ± 0.01a 0.03 ± 0.02a
Brain 0.05 ± 0.04a,b,c,d,e 0.02 ± 0.01a 0.01 ± 0.01a,b,c 0.03 ± 0.01a 0.00 ± 0.00a
Bone 0.16 ± 0.10a,b,c,d,e 0.01 ± 0.01a 0.07 ± 0.03a,b,c 0.03 ± 0.01a 0.03 ± 0.01a
Testis 0.00 ± 0.01a,b,c,d,e 0.00 ± 0.00a 0.01 ± 0.00a,b,c 0.02 ± 0.02a 0.00 ± 0.00a
Tail 2.27 ± 0.67a 4.58 ± 1.90a 3.80 ± 1.52a 1.63 ± 0.55a 1.77 ± 0.66a
Total recovery 63.91 ± 2.89 67.88 ± 4.80 94.10 ± 8.33f,g 82.85 ± 2.70 78.49 ± 4.61
Results are presented as means ± SEM (n = 4).
a 0.05 vs. Liver;
b 0.05 vs. Spleen;
c 0.05 vs. Tail.
d 0.05 vs. Blood.
e 0.05 vs. Lung.
f 0.05 vs. Cit-AuNPs.
g 0.05 vs. MUA-AuNPs.
Fig. 2. Gold concentration in the liver, spleen, lung and blood, 24 h after i.v.
injection with AuNPs (expressed as% of the injected dose). Results are presented as
mean ± SEM (n = 4 per group). ⁄p < 0.05 vs. Cit-AuNPs, #p < 0.05 vs. MUA-AuNPs.
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toxicity were elicited in the rats by any of the tested AuNPs 24 h
after intravenous administration. The injections were well toler-
ated, and rats did not exhibit alterations in behavior. Tissue size,
color and morphology remained unchanged, as compared to sal-
ine-treated rats. No signiﬁcant differences were seen in total body
and organ weights, as compared with control animals (data not
shown). No macroscopic signs of inﬂammation were observed.3.3. Uptake and subcellular localization of the AuNPs
Translocation of the different AuNPs from systemic circulation
to the liver at 24 h after intravenous injection was investigated
by TEM. The AuNPs appeared as electron-dense deposits detected
in the liver tissue, trapped inside hepatocytes (Fig. 3) and Kupffer
cells (Fig. 4). A qualitative analysis of the micrographs suggested
that in the hepatic tissue, all the tested AuNPs preferentially accu-
mulate in Kupffer cells and to a lesser extent in the hepatocytes.
For both type of cells, monodisperse or agglomerates of citrate-,
MUA- and peptide-coated AuNPs were observed inside endosomes.
Freely dispersed AuNPs in the cytosol, within the nucleus or in
other cytoplasmic organelles were not detected. The electron-
dense material was absent in the hepatic tissue of the control ani-
mal (data not shown). Although only one animal/group has beenused in this analysis, the observations were very consistent among
the AuNPs-treated animals and clearly distinct from those ob-
served in the control animal. In addition, Kupffer cells exhibited
signs of necrosis, indicating possible AuNPs-induced injury. A
semi-quantitative analysis of the amount of the different function-
alized AuNPs internalized by the Kupffer cells was performed.
Higher uptake of pentapeptide-coated AuNPs comparing to Cit-
AuNPs was observed (Table 5), which is in agreement with the
quantitative analysis of Au.
4. Discussion
Safe biomedical applications of AuNPs require extensive bioki-
netic assessment. Increasing evidence demonstrates that not only
the chemical nature but other factors such as size, shape and sur-
face functionalization are important determinants of nanomaterial
in vivo dynamics and toxicity [34–36]. The present study compared
the biodistribution proﬁle of anionic AuNPs with different surface
coatings after a single i.v. administration in the rat. The adminis-
trated doses are in the range of those used in previous studies
(summarized in Table 1 of [10]). The selection of the capping
agents was based on previous reports on their stability and solubil-
ity in aqueous dispersions, as well as their ability to prevent nano-
particle aggregation [24,37]. Functionalization of the reference
AuNPs (Cit-AuNPs) by 11-MUA and the pentapeptides CALNN, CAL-
NS and CALND did not induce a signiﬁcant change in size and sur-
face charge (Table 1), indicating that any change in the distribution
pattern of the tested AuNPs would most likely be due to surface-li-
gand interactions with cells and biomolecules.
The kinetic study conducted revealed that the injected Cit-AuN-
Ps are rapidly translocated from the bloodstream into organs as
shown by the higher liver, lung and spleen Au levels compared
to blood levels as early as 0.5 h after injection. Two hours after
injection, the liver and the spleen were the organs with higher con-
tents of Au, which is consistent with previous reports for Cit-AuNPs
with similar size in rat [6,7] and mice [9,14,15]. Our data support
the notion that bare AuNPs have low ability to escape from the
RES [16]. Furthermore, the relatively constant high hepatic Au lev-
els observed during the 24 h indicates that Cit-AuNPs are poorly
eliminated, which has also been previously described even for
long-term (up to 6 months) studies in rats [6] and mice [8,9,13].
Fig. 3. Representative TEM micrographs of rat liver taken 24 h after the intravenous injection of Cit-AuNPs (A), MUA-AuNPs (B), CALND-AuNPs (C), CALNS-AuNPs (D) and
CALNN-AuNPs (E). The AuNPs appeared as electron-dense deposits and images show clusters of AuNPs entrapped in hepatocytes’ endosomes.
Fig. 4. Representative TEM micrographs of rat liver taken 24 h after the intravenous injection of AuNPs, showing nanoparticles entrapped in endosomes (white arrows). The
top and the bottom rows of micrographs depict Kupffer cells containing Cit-AuNPs (A and B), MUA-AuNPs (C and D), CALND-AuNPs (E and F), CALNS-AuNPs (G and H) and
CALNN-AuNPs (I and J). The bottom micrographs correspond to the dashed square marked in the upper row.
Table 5
Semiquantitative TEM analysis of the amount of internalized AuNPs by the Kupffer cells.
NP coating Kupffer cells total observed Kupffer cells containing AuNPs % of Kupffer cells containing AuNPs
Citrate 51 10 20
MUA 45 8 18
CALNN 19 19 28
CALND 55 15 27
CALNS 49 12 24
Results obtained from observations of one animal/group.
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atively large size, since renal excretion would not be expected for
NPs with over 5.5 nm average diameter [38]. In addition, a very
low percentage of the initial injected Au dose remained in the
blood over the time, indicating a rapid translocation of Cit-AuNPs
into the tissues. Similar results have been found by others in rat
[36,39] and mouse [9] after i.v. administration of Cit-AuNPs. How-
ever, De Jong et al. have reported high levels of Cit-AuNPs with dif-
ferent sizes in the blood at 24 h after i.v. administration in the rat
[7].Longer circulation time and minimum uptake by the RES cells
are desirable in terms of better therapeutic efﬁcacy and target-
ability of the AuNPs. Several studies on the kinetics of PEG-func-
tionalized AuNPs revealed longer plasma half-lives for these NPs
[13,14,20–22]; however, liver and spleen remained the major res-
ervoirs. In our study, with the exception of blood levels, MUA-
coated AuNPs distribution pattern was similar to that obtained
for Cit-AuNPs at 24 h after i.v. injection.
According to a recent study by Guerrero et al., capping AuNPs
with an amphipathic peptide sequence appears to be a good strat-
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tide-functionalized AuNPs employed in our study, the general
trend of distribution did not differ from the one described for
Cit-AuNPs; however, increased Au levels in the liver were attained
for CALNN-, CALNS- and CALND-capped AuNPs at 24 h post-injec-
tion, with values signiﬁcantly higher than those found for Cit-AuN-
Ps. Interestingly, this increase in the hepatic Au content was
accompanied by a signiﬁcant decrease in blood Au levels compar-
ing to the observed in Cit-AuNPs-treated rats. The exact reasons for
this different behavior are currently not completely clear but under
investigation. It could be related to differences in stability and/or
interaction with serum proteins between bare and peptide-coated
AuNPs. In fact, we have previously reported that the afﬁnity of pro-
teins to Cit-AuNPs and to AuNPs with thiol-ligands (peptides with
a terminal Cys or other organic molecules) is different, despite the
fact that the functional groups at the outer-surface of the AuNPs
were in both cases carboxylates [40].
Although changes in the peptide sequence could affect the sta-
bility and modify NPs interactions with biomolecules [41], no ma-
jor differences were observed among the three pentapeptide-
functionalized AuNPs employed in our study. This is in line with
the report by Levy et al. who found that changing the terminal ami-
no acid of CALNN to a more negative (CALND) or neutral residue
(CALNS) did not affect the stability of AuNPs comparing to CAL-
NN-coated AuNPs [24]. In addition, Olmedo et al. [41] have shown
that AuNPs functionalized with the peptide CLPFFD-NH2 have
more afﬁnity to b-amyloid ﬁbrils than bare AuNPs supporting the
view that peptide functionalization of AuNPs could enhance their
interactions with biological molecules.
In our study, the percentage of Au recovery ranged from 60% to
90% of the total injected dose. This could be due to Au accumula-
tion in other non-analyzed organs and fractions (e.g. skin, skeleton
and soft tissue), which agrees with previous reports of high per-
centages of the injected dose of radiolabelled AuNPs found in the
remaining carcass [36,39]. In addition, we also analyzed urine
and feces, but the Au levels were below the quantiﬁcation level
excluding their contribution to the Au loss.
Also, the tested dose for each different type of functionalized
AuNP varied slightly comparing to Cit-AuNPs. However, consid-
ering the peptide-coated AuNPs, our results show that in spite
of differences in the administered dose (CALNN-, CALNS-
< Cit-AuNPs; CALND-  Cit-AuNPs), no differences in hepatic
accumulation among these peptide-coated AuNPs were observed.
Therefore, liver accumulation seems to be increased with
the peptide capping. However, the possibility that differences
in dose may inﬂuence the biodistribution pattern cannot be
overruled.
Accumulation of AuNPs in the liver could lead to histological
changes and toxicity [42,43]. The TEM studies of liver tissue sam-
ples from rats exposed to the differently capped AuNPs revealed
the presence of monodisperse and clusters of nanoparticles inside
endosomes of both hepatocytes and Kupffer cells. Endosomal loca-
tion for citrate- and CALNN-coated AuNPs has been also observed
in vitro by Nativo and coworkers in HeLa cells [44]. In Kupffer cells,
the preferential target for all tested AuNPs, signs of necrosis were
observed.
In general, the biodistribution proﬁle for MUA- and pentapep-
tide-capped AuNPs did not differ from citrate-AuNPs. The possibil-
ity of removal of the capping agent after contact with physiological
media leading to the initial bare AuNPs cannot be ruled out. How-
ever, this is less likely to occur as it is expected that the capping
agent remains bound due to the strong binding of thiol groups to
Au surfaces, even in biological media [45]. Nevertheless, additional
studies are needed to determine whether these AuNPs may induce
distinct immunological or metabolic changes. Also, studies exam-
ining biodistribution for longer periods of time can provide valu-able information for a better understanding of the impact of
functionalization in the AuNPs life cycle in the organism.5. Conclusion
With the present study, we have shown that the biodistribution
proﬁle of Cit-AuNPs remains constant in the ﬁrst 24 h after i.v.
administration and that the liver and spleen are the preferential or-
gans for these AuNPs uptake, followed by the lung. Our data show
that functionalization of the AuNPs surface with 11-MUA, CALNN,
CALND or CALNS does not induce signiﬁcant changes in the general
biodistribution pattern relative to the reference Cit-AuNPs. How-
ever, pentapeptide coating signiﬁcantly increased accumulation
in the liver while decreasing levels in circulation, which empha-
sizes the inﬂuence of surface coating on the potential interactions
between the AuNPs and the cellular components responsible for
their recognition and uptake.Acknowledgement
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